Elbasvir
Clinical data | |
---|---|
Trade names | Zepatier (combination with grazoprevir) |
Other names | MK-8742 |
License data | |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | >99.9% |
Metabolism | CYP3A4 |
Elimination half-life | 24 hours |
Excretion | >90% via faeces, <1% via urine |
Identifiers | |
| |
JSmol) | |
| |
|
Elbasvir is a drug approved by the
Elbasvir is a highly potent and selective
NS5A replication complex.[3] It has only been investigated as a combination product with other complementary hepatitis C antiviral drugs such as grazoprevir and MK-3682, and it is unclear whether elbasvir would show robust antiviral activity if it was administered by itself. Nevertheless, combination products of this type represent the most successful approach yet developed for actually curing hepatitis C, rather than merely slowing the progression of the disease.[4]
Side effects
Side effects have only been assessed in the combination with grazoprevir; see Elbasvir/grazoprevir#Side effects.[citation needed]
Interactions
Elbasvir is degraded by the liver enzyme
St. John's wort, can lead to ineffectively low plasma levels of elbasvir. Combination with CYP3A4 inhibitors may increase plasma levels.[5]
Pharmacology
Mechanism of action
The substance blocks
virus replication and assembly.[5]
Pharmacokinetics
Elbasvir reaches peak plasma concentrations three hours after oral intake together with grazoprevir (variation between patients: three to six hours). In hepatitis C patients, steady state concentrations are found after about six days.
alpha-1-acid glycoprotein. Part of the substance is oxidised in the liver, largely by the enzyme CYP3A4. The biological half-life is 24 hours on average. Over 90% are excreted via the faeces, and less than 1% via the urine.[5][6]
References
- ^ FDA approves Zepatier for treatment of chronic hepatitis C genotypes 1 and 4. January 28, 2016
- PMID 25467591.
- S2CID 10543092.
- S2CID 207199323.
- ^ a b c Haberfeld H, ed. (2016). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag.
- ^ FDA Professional Drug Information on Zepatier.